CN109232720A - 一种口蹄疫O型病毒sIgA抗体ELISA检测试剂盒及其应用 - Google Patents
一种口蹄疫O型病毒sIgA抗体ELISA检测试剂盒及其应用 Download PDFInfo
- Publication number
- CN109232720A CN109232720A CN201811068030.0A CN201811068030A CN109232720A CN 109232720 A CN109232720 A CN 109232720A CN 201811068030 A CN201811068030 A CN 201811068030A CN 109232720 A CN109232720 A CN 109232720A
- Authority
- CN
- China
- Prior art keywords
- foot
- mouth disease
- virus
- antibody
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 59
- 238000002965 ELISA Methods 0.000 title claims abstract description 48
- 238000001514 detection method Methods 0.000 title claims abstract description 39
- 241001591005 Siga Species 0.000 title claims abstract description 30
- 239000000427 antigen Substances 0.000 claims abstract description 60
- 108091007433 antigens Proteins 0.000 claims abstract description 60
- 102000036639 antigens Human genes 0.000 claims abstract description 60
- 239000000523 sample Substances 0.000 claims abstract description 57
- 239000000243 solution Substances 0.000 claims abstract description 39
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 108090000790 Enzymes Proteins 0.000 claims abstract description 22
- 102000004190 Enzymes Human genes 0.000 claims abstract description 22
- 241001494479 Pecora Species 0.000 claims abstract description 17
- 239000013642 negative control Substances 0.000 claims abstract description 15
- 239000013641 positive control Substances 0.000 claims abstract description 13
- 239000012895 dilution Substances 0.000 claims abstract description 11
- 238000010790 dilution Methods 0.000 claims abstract description 11
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 56
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims description 26
- 101710132601 Capsid protein Proteins 0.000 claims description 17
- 101710197658 Capsid protein VP1 Proteins 0.000 claims description 17
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims description 17
- 101710108545 Viral protein 1 Proteins 0.000 claims description 17
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 101710172711 Structural protein Proteins 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 241000282898 Sus scrofa Species 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 10
- 230000009465 prokaryotic expression Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 230000003472 neutralizing effect Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 238000008157 ELISA kit Methods 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 5
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 4
- 239000012898 sample dilution Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 210000003000 inclusion body Anatomy 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims 4
- 239000002250 absorbent Substances 0.000 claims 3
- 230000002745 absorbent Effects 0.000 claims 3
- 239000012089 stop solution Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000011888 foil Substances 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 239000012470 diluted sample Substances 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 238000013207 serial dilution Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 abstract description 13
- 238000005215 recombination Methods 0.000 abstract description 13
- 230000003612 virological effect Effects 0.000 abstract description 13
- 238000007865 diluting Methods 0.000 abstract description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 238000004140 cleaning Methods 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000009385 viral infection Effects 0.000 abstract description 3
- 210000003097 mucus Anatomy 0.000 abstract description 2
- 238000006911 enzymatic reaction Methods 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 description 12
- 210000001331 nose Anatomy 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 9
- 239000002574 poison Substances 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001376 precipitating effect Effects 0.000 description 6
- 238000004153 renaturation Methods 0.000 description 6
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 4
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000002850 nasal mucosa Anatomy 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 3
- COYSIHFOCOMGCF-UHFFFAOYSA-N Val-Arg-Gly Natural products CC(C)C(N)C(=O)NC(C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-UHFFFAOYSA-N 0.000 description 3
- 239000005030 aluminium foil Substances 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 108010073093 leucyl-glycyl-glycyl-glycine Proteins 0.000 description 3
- PQKSVQSMTHPRIB-ZKWXMUAHSA-N Asn-Val-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O PQKSVQSMTHPRIB-ZKWXMUAHSA-N 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- FZQLXNIMCPJVJE-YUMQZZPRSA-N Gly-Asp-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FZQLXNIMCPJVJE-YUMQZZPRSA-N 0.000 description 2
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 2
- YJRSIJZUIUANHO-NAKRPEOUSA-N Ile-Val-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)N YJRSIJZUIUANHO-NAKRPEOUSA-N 0.000 description 2
- MJOZZTKJZQFKDK-GUBZILKMSA-N Leu-Ala-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(N)=O MJOZZTKJZQFKDK-GUBZILKMSA-N 0.000 description 2
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 2
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 210000000003 hoof Anatomy 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000004894 snout Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- XWTNPSHCJMZAHQ-QMMMGPOBSA-N 2-[[2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(=O)NCC(O)=O XWTNPSHCJMZAHQ-QMMMGPOBSA-N 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- KVWLTGNCJYDJET-LSJOCFKGSA-N Ala-Arg-His Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KVWLTGNCJYDJET-LSJOCFKGSA-N 0.000 description 1
- AWAXZRDKUHOPBO-GUBZILKMSA-N Ala-Gln-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O AWAXZRDKUHOPBO-GUBZILKMSA-N 0.000 description 1
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 1
- GSHKMNKPMLXSQW-KBIXCLLPSA-N Ala-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C)N GSHKMNKPMLXSQW-KBIXCLLPSA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- YYOVLDPHIJAOSY-DCAQKATOSA-N Arg-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N YYOVLDPHIJAOSY-DCAQKATOSA-N 0.000 description 1
- RKQRHMKFNBYOTN-IHRRRGAJSA-N Arg-His-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N RKQRHMKFNBYOTN-IHRRRGAJSA-N 0.000 description 1
- LLUGJARLJCGLAR-CYDGBPFRSA-N Arg-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N LLUGJARLJCGLAR-CYDGBPFRSA-N 0.000 description 1
- NGYHSXDNNOFHNE-AVGNSLFASA-N Arg-Pro-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O NGYHSXDNNOFHNE-AVGNSLFASA-N 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- QHBMKQWOIYJYMI-BYULHYEWSA-N Asn-Asn-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O QHBMKQWOIYJYMI-BYULHYEWSA-N 0.000 description 1
- XLDMSQYOYXINSZ-QXEWZRGKSA-N Asn-Val-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N XLDMSQYOYXINSZ-QXEWZRGKSA-N 0.000 description 1
- VAWNQIGQPUOPQW-ACZMJKKPSA-N Asp-Glu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VAWNQIGQPUOPQW-ACZMJKKPSA-N 0.000 description 1
- XLILXFRAKOYEJX-GUBZILKMSA-N Asp-Leu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O XLILXFRAKOYEJX-GUBZILKMSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- XXDLUZLKHOVPNW-IHRRRGAJSA-N Cys-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N)O XXDLUZLKHOVPNW-IHRRRGAJSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- XFAUJGNLHIGXET-AVGNSLFASA-N Gln-Leu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XFAUJGNLHIGXET-AVGNSLFASA-N 0.000 description 1
- IHSGESFHTMFHRB-GUBZILKMSA-N Gln-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(N)=O IHSGESFHTMFHRB-GUBZILKMSA-N 0.000 description 1
- LURQDGKYBFWWJA-MNXVOIDGSA-N Gln-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N LURQDGKYBFWWJA-MNXVOIDGSA-N 0.000 description 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 1
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 1
- FHPXTPQBODWBIY-CIUDSAMLSA-N Glu-Ala-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FHPXTPQBODWBIY-CIUDSAMLSA-N 0.000 description 1
- SRZLHYPAOXBBSB-HJGDQZAQSA-N Glu-Arg-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SRZLHYPAOXBBSB-HJGDQZAQSA-N 0.000 description 1
- HMJULNMJWOZNFI-XHNCKOQMSA-N Glu-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N)C(=O)O HMJULNMJWOZNFI-XHNCKOQMSA-N 0.000 description 1
- DJTXYXZNNDDEOU-WHFBIAKZSA-N Gly-Asn-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)C(=O)N DJTXYXZNNDDEOU-WHFBIAKZSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- GUXQAPACZVVOKX-AVGNSLFASA-N His-Lys-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N GUXQAPACZVVOKX-AVGNSLFASA-N 0.000 description 1
- YEKYGQZUBCRNGH-DCAQKATOSA-N His-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)N)C(=O)N[C@@H](CO)C(=O)O YEKYGQZUBCRNGH-DCAQKATOSA-N 0.000 description 1
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 1
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 1
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 1
- 101000640813 Homo sapiens Sodium-coupled neutral amino acid transporter 2 Proteins 0.000 description 1
- 101000716973 Homo sapiens Thialysine N-epsilon-acetyltransferase Proteins 0.000 description 1
- OVPYIUNCVSOVNF-ZPFDUUQYSA-N Ile-Gln-Pro Natural products CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O OVPYIUNCVSOVNF-ZPFDUUQYSA-N 0.000 description 1
- LNJLOZYNZFGJMM-DEQVHRJGSA-N Ile-His-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N LNJLOZYNZFGJMM-DEQVHRJGSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- QDSKNVXKLPQNOJ-GVXVVHGQSA-N Leu-Gln-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O QDSKNVXKLPQNOJ-GVXVVHGQSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- FZIJIFCXUCZHOL-CIUDSAMLSA-N Lys-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN FZIJIFCXUCZHOL-CIUDSAMLSA-N 0.000 description 1
- RZHLIPMZXOEJTL-AVGNSLFASA-N Lys-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)N RZHLIPMZXOEJTL-AVGNSLFASA-N 0.000 description 1
- QQUJSUFWEDZQQY-AVGNSLFASA-N Lys-Gln-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN QQUJSUFWEDZQQY-AVGNSLFASA-N 0.000 description 1
- RQILLQOQXLZTCK-KBPBESRZSA-N Lys-Tyr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O RQILLQOQXLZTCK-KBPBESRZSA-N 0.000 description 1
- LRALLISKBZNSKN-BQBZGAKWSA-N Met-Gly-Ser Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LRALLISKBZNSKN-BQBZGAKWSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241001149897 Plethobasus cyphyus Species 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- FYQSMXKJYTZYRP-DCAQKATOSA-N Pro-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FYQSMXKJYTZYRP-DCAQKATOSA-N 0.000 description 1
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 1
- IIRBTQHFVNGPMQ-AVGNSLFASA-N Pro-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 IIRBTQHFVNGPMQ-AVGNSLFASA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 1
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 1
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 1
- 102100020926 Thialysine N-epsilon-acetyltransferase Human genes 0.000 description 1
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- AKLNEFNQWLHIGY-QWRGUYRKSA-N Tyr-Gly-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N)O AKLNEFNQWLHIGY-QWRGUYRKSA-N 0.000 description 1
- 101150024766 VP1 gene Proteins 0.000 description 1
- ZLFHAAGHGQBQQN-AEJSXWLSSA-N Val-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZLFHAAGHGQBQQN-AEJSXWLSSA-N 0.000 description 1
- COYSIHFOCOMGCF-WPRPVWTQSA-N Val-Arg-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-WPRPVWTQSA-N 0.000 description 1
- YTUABZMPYKCWCQ-XQQFMLRXSA-N Val-His-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N YTUABZMPYKCWCQ-XQQFMLRXSA-N 0.000 description 1
- WBAJDGWKRIHOAC-GVXVVHGQSA-N Val-Lys-Gln Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O WBAJDGWKRIHOAC-GVXVVHGQSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000003115 checkerboard titration Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 150000002411 histidines Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
- G01N2333/09—Foot-and-mouth disease virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种口蹄疫O型病毒sIgA抗体的ELISA检测试剂盒及其应用。所述的试剂盒包括口蹄疫O型病毒广谱多表位重组抗原包被的酶标反应板,100×浓缩酶标抗体、酶标抗体稀释液、样品稀释液、浓缩洗涤液、显色液、终止液、阳性对照样品和阴性对照样品。所述的口蹄疫O型病毒广谱多表位重组抗原由中国型(Cathay)、泛亚型(PanAsia)、缅甸98三个谱系口蹄疫O型病毒代表毒株的主要中和性抗原表位组成,因此提高了试剂盒检测的灵敏性和特异性,并且适用于不同的口蹄疫O型病毒感染的检测。本发明提供的试剂盒适于检测猪、牛、羊三种易感动物黏膜分泌物中的sIgA抗体,对于防治口蹄疫O型病毒的传播和感染具有重要的意义。
Description
技术领域
本发明涉及一种口蹄疫O型病毒sIgA抗体间接ELISA检测试剂盒及其检测方法。本发明属于生物检测技术领域。
背景技术
口蹄疫(Foot-and-Mouth Disease,FMD)是由口蹄疫病毒引起以患病动物的口、蹄部出现水疱性疾病为特征的传染性疾病。口蹄疫病毒(Foot-and-Mouth Disease Virus,FMDV)属于小RNA病毒科,病毒中心是一条单链RNA。根据血清型特性可分为A型、O型、C型、SAT1型、SAT2型、SAT3型(即南非1、2、3型)和Asial(亚洲1型)7个血清型,不同血清型之间几乎没有免疫保护力,感染了一种血清型FMDV的动物仍可感染另一种血清型的FMDV而发病。MDV核酸分子为单股正链的RNA分子,基因组全长约8500个碱基,只含有一个大的开放阅读框,表达产生的聚蛋白逐级裂解产生病毒的结构蛋白(VP1、VP2、VP3、VP4)和非结构蛋白(Lab,2A、2B、2C、3A、3B、3C、3D),结构蛋白组装产生病毒的衣壳结构,非结构蛋白则参与病毒与宿主的相互作用、抑制宿主细胞的转录翻译机制、参与病毒的复制过程。病毒衣壳蛋白是诱导产生中和抗体的主要免疫原,在结构蛋白上存在多个构象性的与线性的中和表位。早期通过单克隆抗体与免疫逃逸突变株的序列分析研究表明,在O型FMDV至少存在5个功能独立的中和性抗原表位,组成抗原位点的区段主要包括VP1的G-H环以及其C端氨基酸,VP2的31,70~73,75和77位氨基酸,VP1B-C环的43和44位点氨基酸;VP3的58位氨基酸,VP1149位氨基酸等参与构成五个中和表位。这5个中和表位除了由VP1G-H环构成的位点1为线性表位外,其余均为构象表位。FMDV的四种结构蛋白VP1、VP2、VP3、VP4中VP1的G-H环的氨基酸很容易变异,但其中的精氨酸-甘氨酸-天门冬氨酸(Arg-Gly-Asp(RGD))高度保守。G-H环的跨度大约是VP1的140-160位的20个氨基酸残基。VP1蛋白上不仅存在主要的抗原位点(141-160aa,200-213aa和21-40aa),而且含有FMD病毒的宿主识别位点。因此选择该区域基因构建表达载体表达纯化的蛋白可以作为良好的制备抗体检测试剂盒的备选包被抗原。
通过原核表达系统制备的多表位抗原生产过程不涉及活病毒,不存在散毒的风险;既可随时根据流行毒株的变化调整表位序列,也可使用不同的抗原序列,增加抗原的广谱性。本发明针对中国型(Cathay)、泛亚、缅甸98三个谱系的口蹄疫O型代表毒株O/Akesu/58(NCBI登录号:AF511039.1)、O/TAW/81/97(NCBI登录号:AJ296321.1)、O/Tibet/99(NCBI登录号:AJ318830.1)、O/Mya98(NCBI登录号:AJ303521.1),采用生物信息学方法对这4株毒株VP1结构蛋白进行精确分析,筛选出优势抗原表位,用原核表达系统表达纯化得到口蹄疫O型代表毒株的主要中和性抗原表位区,制备出更新更全的包被抗原,建立了口蹄疫O型病毒sIgA抗体间接ELISA检测方法及其检测试剂盒。
sIgA抗体作为黏膜免疫的主要效应因子,广泛存在于初乳、泪液、唾液等分泌液中,它不仅可以在第一时间中和病毒,而且可通过黏膜的方式进一步激活系统免疫反应,进而阻止病毒的侵入。其主要功能有:阻抑黏附,免疫排除,溶解细菌,中和病毒,介导抗体依赖的细胞介导的细胞毒性作用(ADCC,antibody-dependent cell-mediatedcytotoxicity),抗炎症,促进天然因子作用及调节黏膜免疫反应。抗口蹄疫病毒sIgA抗体是口蹄疫病毒感染或者疫苗黏膜免疫后首先在呼吸道和消化道产生特异性的标志,同时也反应了黏膜免疫疫苗的效果。目前市场上还没有能够有效检测口蹄疫病毒sIgA抗体的试剂盒,鉴于近年来对黏膜免疫机制和黏膜免疫疫苗研究的深入,开发一种检测黏膜分泌物中口蹄疫病毒sIgA抗体水平的ELISA试剂盒,能够更加准确地反应口蹄疫病毒感染和黏膜免疫状态,同时利用该方法监测口蹄疫病毒sIgA抗体动态变化规律,为口蹄疫黏膜免疫疫苗和建立配套检测方法提供了理论与实验依据。
发明内容
本发明的目的就是针对上述现有技术中的缺陷,提供了一种口蹄疫O型病毒sIgA抗体的检测试剂盒及其方法。
为了实现上述目的,本发明提供的技术方案为:
本发明运用DNAStar软件对针对中国型(Cathay)、泛亚、缅甸98三个谱系的口蹄疫O型代表毒株O/Akesu/58(NCBI登录号:AF511039.1)、O/TAW/81/97(NCBI登录号:AJ296321.1)、O/Tibet/99(NCBI登录号:AJ318830.1)、O/Mya98(NCBI登录号:AJ303521.1),采用生物信息学方法对这4株毒株VP1结构蛋白进行精确分析,筛选出主要中和性抗原表位,设计抗原表位基因的串联顺序为:(O/Akesu/58)VP1 132-160-GGGS-VP1 193-213-GGGS-(O/TAW/81/97)VP1 132-160-GGGS-VP1193-213-GGGS-(O/Tibet/99)VP1132-160-GGGS-VP1 193-213-GGGS-(O/Mya98)VP1 132-160-GGGS-VP1 193-213-6×His,各表位之间以GGGS相连,最后加6组氨酸标签序列,有利于表达蛋白的纯化。设计好的序列交由南京GenScript公司进行编码序列的优化与合成。
本发明得到的一种口蹄疫O型病毒广谱多表位重组抗原,所述的口蹄疫O型病毒广谱多表位重组抗原包含口蹄疫O型病毒代表毒株O/Akesu/58、O/TAW/81/97、O/Tibet/99、O/Mya98的VP1蛋白中的第132-160位、第193-213位的主要中和性抗原表位序列,所述的口蹄疫O型病毒广谱多表位重组抗原的氨基酸序列如SEQ ID NO.2所示。
编码所述的口蹄疫O型病毒广谱多表位重组抗原的核苷酸序列也在本发明的保护范围之内,优选的,所述的核苷酸序列如SEQ ID NO.1所示。
进一步的,本发明还提出了所述的口蹄疫O型病毒广谱多表位重组抗原在制备检测口蹄疫O型病毒sIgA抗体试剂中的用途。优选的,所述的试剂为试剂盒。
更进一步的,本发明提出了一种口蹄疫O型病毒sIgA抗体ELISA检测试剂盒,所述试剂盒包括所述的口蹄疫O型病毒广谱多表位重组抗原包被的酶标板、100×浓缩酶标抗体、酶标抗体稀释液、样品稀释液、浓缩洗涤液、显色液、终止液、阳性对照样品和阴性对照样品。
其中,优选的,所述口蹄疫O型病毒广谱多表位重组抗原是经原核表达系统表达获得。
其中,优选的,所述的口蹄疫O型病毒广谱多表位重组抗原包被的酶标板按照以下方法制备得到:
(1)包被抗原的制备和包被
原核表达系统表达获得的重组蛋白包涵体经复性及Ni-NTA纯化得到口蹄疫O型病毒广谱多表位重组抗原,其氨基酸序列如SEQ ID NO.2所示,包被时用pH9.6的碳酸盐缓冲液稀释至3μg/ml,按照100μl/孔包被酶标板,4℃冰箱静置过夜;
(2)酶标板的封闭与保存
包被过夜的酶标板用PBST洗涤4次拍干,每孔加100μl含0.5w/v%BSA的10mM PBS封闭液,37℃放置2h,弃掉封闭液,PBST洗涤3遍,得到预包被抗原的酶标板,每孔加100μl含6v/v%马血清的酶标板稳定剂,室温放置30min,弃掉液体后自然晾干,用铝箔袋真空封口,4℃保存;
其中,所述的酶标板稳定剂是将5g BSA、10g蔗糖、20g海藻糖,加入到1000ml0.01mol/LPBS(pH7.4)中轻轻震荡至溶解,加0.05w/v%Procline300,保存于4℃备用。
其中,优选的,所述阳性对照样品是采集口蹄疫O型病毒攻毒后7-21d猪、牛以及羊的鼻拭子样品,经混合、一系列稀释后检测OD450值为1.5±0.05的样品;所述阴性样品是 FMDV NS试剂盒检测口蹄疫病毒非结构蛋白抗体为阴性,口蹄疫A型、O型、AsiaI液相阻断ELISA试剂盒检测血清抗体效价<1/4,FMDV特异性PCR检测抗原为阴性的猪、牛以及羊的鼻拭子,经混合、稀释后检测OD450值为0.1±0.05的样品,无菌分装备用。
其中,优选的,所述的100×浓缩酶标抗体为辣根过氧化物酶(HRP)标记鼠抗猪、牛或羊IgA的单克隆抗体,使用时,用酶标抗体稀释液100倍稀释后使用,所述的酶标抗体稀释液是含有1v/v%甘油、0.5w/v%牛血清白蛋白、1w/v%酪蛋白以及0.05w/v%Procline300的0.01mol/LPBS缓冲液,pH7.4。
其中,优选的,所述的样品稀释液为含0.5M NaCl、2.68mM KCl、2.79mM KH2PO4、8.1mM Na2HPO4、5g/L酪蛋白、0.05%Tween20和10mM PBS的混合溶液;所述的显色液为TMB显色液,所述的终止液为1moL/L H2SO4溶液;所述的浓缩洗涤液为10×PBST溶液,即含有0.5v/v%Tween20的0.1mol/L PBS溶液,pH7.6,使用时稀释10倍。
其中,优选的,利用本发明所述的试剂盒进行口蹄疫O型病毒sIgA抗体检测时,按照以下步骤进行:
(1)样本稀释
将待测样本、阳性对照以及阴性对照用样品稀释液按体积比1:2进行稀释;
(2)洗板
从4℃冰箱中取出口蹄疫O型病毒代表毒株主要中和性抗原表位(TB/O)蛋白包被的酶标板,打开铝箔袋,取出酶标板,以稀释好的洗涤液洗板3次,吸水纸拍干,每次3min;
(3)加样
将稀释后的待测样本、阳性对照以及阴性对照分别加入酶标板中,每孔100μL,37℃孵育45min;
(4)洗涤
取出酶标板,甩掉样品,用洗涤液漂洗4次,吸水纸拍干;
(5)加入酶标抗体
加入稀释好的辣根过氧化物酶标记的鼠抗猪、牛或羊IgA单克隆抗体,100μL/孔,37℃工作30min;
(6)加底物:
甩掉酶标抗体,用洗涤液漂洗4次,吸水纸拍干,加入显色液37℃显色15min,取出后立即加入终止液;
(7)结果判定
在酶标仪上读取OD450nm数值,待测样本的OD450nm值大于等于阴性对照样品平均值的2.5倍判为阳性,小于阴性对照样品平均值的2.5倍判为阴性。
本发明的技术要点为:
1、以原核表达系统表达的口蹄疫O型病毒广谱多表位重组抗原作为包被抗原,以酶标记的鼠抗猪、牛或羊IgA的单克隆抗体为二抗,待检样品与包被抗原反应后,通过酶标记抗体的进一步反应,最后与参考阳性鼻拭子和阴性鼻拭子对比,来评价口蹄疫病毒sIgA抗体水平。
2、包被抗原是经大肠杆菌pET-30a(+)原核表达后纯化的含有口蹄疫O型代表毒株主要中和性抗原表位的重组蛋白,该抗原由中国型(Cathay)、泛亚型(PanAsia)、缅甸98三个谱系口蹄疫O型病毒代表毒株的主要中和性抗原表位组成,而且含有口蹄疫病毒的宿主识别位点(RGD三肽基序),具有广谱性。
3、二抗是用辣根过氧化物酶(HRP)标记试剂盒标记的鼠抗猪、牛或羊IgA的单克隆抗体。
4、参考阳性样品是实验室攻毒后7-21天感染口蹄疫的猪、牛以及羊的鼻拭子的混合物;阴性样品是经 FMDV NS试剂盒检测口蹄疫病毒非结构蛋白抗体为阴性,A型、O型、AsiaI口蹄疫液相阻断ELISA试剂盒检测抗体效价<1/4,FMDV特异性PCR检测抗原为阴性的猪、牛以及羊的鼻拭子的混合物。
相较于现有技术,本发明的有益效果为:
1)本发明公开了一种检测口蹄疫O型病毒sIgA抗体的方法及其检测试剂盒,通过包被抗原、HRP标记的鼠抗猪、牛、羊IgA的单克隆抗体,提供了一种评价口蹄疫黏膜免疫效果的有效方法,并为口蹄疫感染的早期诊断提供了一种新方法,能够快速、准确的检测猪、牛、羊鼻拭子中的口蹄疫A型病毒sIgA抗体;
2)由于口蹄疫病毒近些年流行毒的突变发生频率越来越高,本发明通过原核表达系统表达了4株口蹄疫O型代表毒株的优势抗原表位作为包被抗原,该抗原由中国型(Cathay)、泛亚型(PanAsia)、缅甸98三个谱系口蹄疫O型病毒代表毒株的主要中和性抗原表位组成,从而制备出新的、具有广谱性的包被抗原,提高了试剂盒对现有毒株的检出能力;
3)样品的采集操作简便,人力消耗小,对动物的应激小;
4)该方法操作简便,所需时间短,可以用于大量样品的检测和黏膜免疫效果的评价。
附图说明
图1是本发明实施例提供的EB/O蛋白SDS-PAGE图;
图中:泳道M1:蛋白分子量标准;泳道1:BSA蛋白;泳道2:EB/O蛋白;
图2是本发明实施例提供的纯化蛋白结果。
图中:泳道M:蛋白分子量标准;泳道1、2:洗脱蛋白。
具体实施方式
下面结合具体实施例对本发明做进一步说明,但下述实施例不会在任何方面限制本发明的保护范围。
实施例1口蹄疫O型病毒sIgA抗体ELISA检测试剂盒的制备及组装
(一)试剂盒的制备:
1、口蹄疫O型病毒代表毒株的主要中和性抗原表位(EB/O)的设计:
口蹄疫病毒结构蛋白VP1是病毒的优势抗原,无论是分离纯化的天然VP1蛋白还是重组表达产物都能诱导机体产生保护性中和抗体,具有型特异性。口蹄疫病毒VP1基因全长由639个核苷酸组成,编码一条具有213个氨基酸的蛋白,其主要抗原表位集中在第140-160位的氨基酸和第200-213位的氨基酸区段。本发明用DNAStar生物软件对我国分离的4株口蹄疫O型病毒代表毒株O/Akesu/58(NCBI登录号:AF511039.1)、O/TAW/81/97(NCBI登录号:AJ296321.1)、O/Tibet/99(NCBI登录号:AJ318830.1)、O/Mya98(NCBI登录号:AJ303521.1)的VP1基因序列分析,确定了中和性抗原表位132-160、193-213位的氨基酸区段。设计抗原表位的串联顺序为:
(O/Akesu/58)VP1 132-160-GGGS-VP1 193-213-GGGS-(O/TAW/81/97)VP1 132-160-GGGS-VP1193-213-GGGS-(O/Tibet/99)VP1132-160-GGGS-VP1 193-213-GGGS-(O/Mya98)VP1 132-160-GGGS-VP1 193-213-6×His,各表位之间以GGGS相连,最后加6组氨酸标签序列,有利于表达蛋白的纯化。
最终获得的编码主要中和性抗原表位(EB/O)抗原的核苷酸序列如SEQ ID No.1所示,其氨基酸序列如SEQ ID No.2所示,多表位基因序列委托南京金斯瑞生物科技公司合成。
2、口蹄疫O型病毒主要中和性抗原表位(EB/O)蛋白的表达:
将口蹄疫O型病毒主要中和性抗原表位(EB/O)编码基因705bp(SEQ ID NO.1所示)克隆到pET-30a(+)原核表达载体,经酶切、测序正确后,阳性质粒转化至BL21DE3plysS菌株,卡那霉素抗性TB平板筛选单克隆,37℃,TB培养基摇菌过夜;将过夜菌液按体积比(v/v)1:100转接至新鲜TB培养基,37℃,200rpm摇3h至OD600值达到4左右,加入终浓度1mmol/L的IPTG继续摇菌3h,6000rpm离心收集菌液。降低培养温度到30℃;加入IPTG诱导剂至终浓度0.5mM,30℃继续震荡培养3-4h;8000rpm离心3min收集菌体,重悬于50mL预冷NTA-0缓冲液中,冰浴30min;超声破碎菌体,16000rpm 4℃离心50min,收集上清以及沉淀;取少量上清及沉淀进行SDS-PAGE检测,蛋白表达结果如图1所示。剩余上清及沉淀置于4℃备用。
3、蛋白纯化、复性:
沉淀以50mL NTA-0缓冲液重悬,加入DTT至终浓度1mM,超声促进杂蛋白溶解,离心收集沉淀,重复三次至上清透明,沉淀以PBS重悬,超声,离心去上清,以6M盐酸胍重悬包涵体,加DTT至终浓度5mM;37℃震荡3h至包涵体全部溶解,离心去上清。再用蛋白复性液将蛋白低温透析复性,以2倍体积的3M盐酸胍稀释蛋白溶液,在4℃下逐滴加入到200mL复性液(pH8.0)中,转速调节至最大,搅拌24h,取蛋白溶液于透析袋中,以PEG60000浓缩后以PBS缓冲液透析过夜。复性后的蛋白用阴离子交换柱Ni-NTA再次纯化,收集蛋白。蛋白纯化结果如图2所示。
4、包被抗原的制备与最佳包被浓度的选择:
纯化蛋白用碳酸盐缓冲液(pH9.6)系列稀释成6μg/mL,3μg/mL,1.5μg/mL,0.75μg/mL,0.38μg/mL,0.19μg/mL,每个浓度包被两列,按照100μL/孔加到96孔酶标板上,4℃包被过夜。结果表明,包被抗原浓度为3μg/mL时阳性值OD450值大于1.0,且P/N的值最大,因此确定该浓度为最佳包被浓度(表1)。
表1棋盘滴定抗原工作浓度(OD450nm)
| 包被浓度(μg/mL) | 6.00 | 3.00 | 1.50 | 0.75 | 0.38 | 0.19 |
| 阳性样品(P) | 1.122 | 1.084 | 0.916 | 0.746 | 0.653 | 0.554 |
| 阴性样品(N) | 0.138 | 0.098 | 0.092 | 0.087 | 0.079 | 0.073 |
| P/N | 8.130 | 11.06 | 9.956 | 8.575 | 8.266 | 7.589 |
5、酶标板的封闭:
上述酶标板用PBST(含0.5v/v%Tween20的0.01mol/L PBS溶液,pH 7.6)洗4次,每孔加100μl含0.5w/v%BSA的10mM PBS封闭液,37℃放置2 h。弃掉封闭液,PBST洗涤3遍,得到预包被抗原的酶标板,每孔加100μl含6v/v%马血清的酶标板稳定剂,室温放置30min,弃掉液体后自然晾干,用铝箔袋真空封口,4℃保存;
其中,所述的酶标板稳定剂是将5g BSA、10g蔗糖、20g海藻糖,加入到1000ml0.01mol/L PBS(pH7.4)中轻轻震荡至溶解,加0.05w/v%Procline300,保存于4℃备用。
6、标准阴、阳性鼻试子的制备:
所述阳性对照样品是采集口蹄疫O型病毒攻毒后7-21d猪、牛以及羊的鼻拭子样品,经混合、一系列稀释后检测OD450值为1.5±0.05的样品;所述阴性对照样品是 FMDV NS试剂盒检测口蹄疫病毒非结构蛋白抗体为阴性,口蹄疫A型、O型、AsiaI液相阻断ELISA试剂盒检测血清抗体效价<1/4,FMDV特异性PCR检测抗原为阴性的猪、牛以及羊的鼻拭子,经混合、稀释后检测OD450值为0.1±0.05的样品,无菌分装备用。
7、酶标抗体(10×)
辣根过氧化物酶标记的鼠抗猪、牛或羊IgA二抗,使用时稀释10倍使用。
8、样品稀释液
样品稀释液为含0.5M NaCl、2.68mM KCl、2.79mM KH2PO4、8.1mM Na2HPO4、5g/L酪蛋白、0.05%v/vTween20和10mM PBS的混合溶液。
9、PBST(10×)
含有0.5v/v%Tween20的0.1mol/LPBS溶液,pH 7.6。使用时稀释10倍使用。
10、显色液以及终止液
显色液为TMB显色液,终止液为1moL/LH2SO4溶液。
(二)试剂盒的组装及保存
按照表2所列的试剂盒内容,装配试剂盒,组成后装于4℃保存。
表2 ELISA检测试剂盒内容
(三)试剂盒的使用方法(检测方法)
(1)稀释:用灭菌水将PBST(10×)洗液稀释至250ml,以样品稀释液将酶标抗体(10×)稀释至5ml。
(2)洗板:打开包装袋,取出预包被抗原的酶标板,以稀释好的PBST洗板4次,吸水纸拍干,每次3min。
(3)加样:将样品以1:2倍稀释,每孔100ul加入到反应板中,加入阳性对照与阴性对照,100μL/孔,该阳性对照、阴性对照分别做两个重复。37℃孵育45min。
(4)加酶标抗体:甩掉样品,用PBST漂洗4次,吸水纸拍干,加入稀释好的辣根过氧化物酶标记的鼠抗猪、牛或羊IgA二抗,100μL/孔,37℃孵育30min。
(5)加底物:甩掉酶标抗体,用PBST漂洗4次,吸水纸拍干。加入TMB显色液37℃孵育15min,然后加入100μl/孔的反应终止液。
(6)在酶标仪上读取OD450数值。
在酶标仪上读取OD450数值,待测样本的OD450nm值大于等于阴性对照血清平均值的2.5倍判为阳性,小于阴性对照血清平均值的2.5倍判为阴性。
实施例2口蹄疫O型病毒sIgA抗体ELISA检测试剂盒的敏感性、特异性实验
1、敏感性实验:
利用实施例1制备得到试剂盒检测100份鼻试子样品,这些样品是分别采用O/Akesu/58、O/TAW/81/97、O/Tibet/99、O/Mya98实验攻毒后收集的发病猪的鼻试子样品,每种病毒样本为25例,在进行攻毒之前未进行任何免疫,检测方法同实施例1。通过计算阳性检出率分析该方法的敏感性。ELISA检测结果表明以上样品阳性93份,阴性7份,阳性检出率为93%。说明本发明的试剂盒具有较好的敏感性,并且能够检测不同的口蹄疫O型病毒的感染。结果如表3所示。
表3 ELISA试剂盒敏感性试验
| 检测方法 | 样品数(份) | 阳性数(份) | 阴性数(份) | 阳性率(%) |
| 间接ELISA | 100 | 93 | 7 | 93% |
2、特异性实验:
利用实施例1制备得到试剂盒检测了猪流行性腹泻病毒(PEDV)感染仔猪肠黏膜冲洗液样品、猪繁殖与呼吸综合征病毒(PRRSV)抗体阳性样品、猪圆环病毒(PCV)特异性IgA抗体阳性样品、猪瘟病毒(CSFV)特异性IgA抗体阳性样品,针对A型、O型FMDV交叉感染情况,增加90份A型FMDV感染猪鼻拭子样品进行检测,以A型FMDV阳性样品作为阳性对照,分析该方法的特异性。ELISA检测结果表明90份A型FMDV感染猪鼻拭子样品阳性2份,可疑10份,阴性78份,符合率为86.7%。且与猪流行性腹泻病毒(PEDV)、猪繁殖与呼吸综合征病毒(PRRSV)、猪圆环病毒(PCV)、猪瘟病毒的IgA抗体都没有交叉反应,保证了该诊断试剂盒同时具有良好的敏感性和特异性,从根本上保证了结果的准确性和可靠性。
3、重复性实验
选取6份不同抗体水平的阳性鼻粘膜试子样品和1份阴性鼻粘膜试子样品,采用同一批次抗原包被ELISA板,在不同时间进行4次批内重复试验,统计检测结果,批内变异系数小于9%(1.41%~8.64%)。表明同一份鼻粘膜试子样品在同一批次制备的抗原包被的ELISA板内变异系数很小,具有良好的重复性。采用4个批次制备的抗原包被ELISA板在同一时间进行批间重复试验,统计检测结果,批间变异系数小于8%(2.28%~7.13%),表明同一份鼻粘膜试子样品在不同批次制备的抗原包被的ELISA板内变异系数也很小,说明本发明建立的间接ELISA方法具有很好的重复性(表4)。
表4重复性实验
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
序列表
<110> 中国农业科学院兰州兽医研究所
<120> 一种口蹄疫O型病毒sIgA抗体ELISA检测试剂盒及其应用
<160>2
<170>Patent-In 3.5
<210>1
<211>705
<212>DNA
<213> artificial sequence
<400>1
atgggaagct gcaggtacag caacagtaac gtgagcaacg tgagtggtga tctccaagtg 60
ttggctcaga aggcggcgag agcgctgcct ggaggaggaa gcgccatcca cccgagtgag 120
gctagacaca agcagaagat tgtggcaccc gcaaaacagc ttttgggagg aggaagcggg 180
agcagtaagt acggtgacac cagcactaac aacgtgagag gtgaccttca agtgttagct 240
cagaaggcag aaagaactct gcctggagga ggaagcgcca ttcaaccgag tgacgctaga 300
cacaagcaga ggattgtggc acccgcaaaa cagcttctgg gaggaggaag cgggaactgc 360
aagtatggcg agagccccgt gaccaatgtg agaggtgacc tgcaagtatt ggcccagaag 420
gcggcaagaa cgctgcctgg aggaggaagc gctattcacc cgagcgaagc tagacacaaa 480
caaaagattg tggcgcctgt gaaacagctt ttgggaggag gaagcgggaa ctgcaagtac 540
gccgagggct cactgaccaa cgtgagaggt gatctccagg tgctggctca gaaggcggcg 600
aggccgctgc ctggaggagg aagcgctgtc catccggatg aggctagaca caaacagaaa 660
atagtggcac ctgtgaagca gtccttgcac caccaccacc accac 705
<210>2
<211>235
<212>PRT
<213>artificial sequence
<400>2
Met Gly Ser Cys Arg Tyr Ser Asn Ser Asn Val Ser Asn Val Ser Gly Asp Leu Gln Val 20
Leu Ala Gln Lys Ala Ala Arg Ala Leu Pro Gly Gly Gly Ser Ala Ile His Pro Ser Glu 40
Ala Arg His Lys Gln Lys Ile Val Ala Pro Ala Lys Gln Leu Leu Gly Gly Gly Ser Gly 60
Ser Ser Lys Tyr Gly Asp Thr Ser Thr Asn Asn Val Arg Gly Asp Leu Gln Val Leu Ala 80
Gln Lys Ala Glu Arg Thr Leu Pro Gly Gly Gly Ser Ala Ile Gln Pro Ser Asp Ala Arg 100
His Lys Gln Arg Ile Val Ala Pro Ala Lys Gln Leu Leu Gly Gly Gly Ser Gly Asn Cys 120
Lys Tyr Gly Glu Ser Pro Val Thr Asn Val Arg Gly Asp Leu Gln Val Leu Ala Gln Lys 140
Ala Ala Arg Thr Leu Pro Gly Gly Gly Ser Ala Ile His Pro Ser Glu Ala Arg His Lys 160
Gln Lys Ile Val Ala Pro Val Lys Gln Leu Leu Gly Gly Gly Ser Gly Asn Cys Lys Tyr 180
Ala Glu Gly Ser Leu Thr Asn Val Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Ala 200
Arg Pro Leu Pro Gly Gly Gly Ser Ala Val His Pro Asp Glu Ala Arg His Lys Gln Lys 220
Ile Val Ala Pro Val Lys Gln Ser Leu His His His His His His 235
Claims (10)
1.一种口蹄疫O型病毒广谱多表位重组抗原,其特征在于,所述的口蹄疫O型病毒广谱多表位重组抗原包含口蹄疫O型病毒代表毒株O/Akesu/58、O/TAW/81/97、O/Tibet/99、O/Mya98的VP1蛋白中的第132-160位、第193-213位的主要中和性抗原表位序列,所述的口蹄疫O型病毒广谱多表位重组抗原的氨基酸序列如SEQ ID NO.2所示。
2.编码权利要求1所述的口蹄疫O型病毒广谱多表位重组抗原的核苷酸序列,优选的,所述的核苷酸序列如SEQ ID NO.1所示。
3.权利要求1所述的口蹄疫O型病毒广谱多表位重组抗原在制备检测口蹄疫O型病毒sIgA抗体试剂中的用途。
4.一种口蹄疫O型病毒sIgA抗体ELISA检测试剂盒,其特征在于,所述试剂盒包括权利要求1所述的口蹄疫O型病毒广谱多表位重组抗原包被的酶标板、100×浓缩酶标抗体、酶标抗体稀释液、样品稀释液、浓缩洗涤液、显色液、终止液、阳性对照样品和阴性对照样品。
5.如权利要求4所述的口蹄疫O型病毒sIgA抗体ELISA检测试剂盒,其特征在于,所述口蹄疫O型病毒广谱多表位重组抗原是经原核表达系统表达获得。
6.如权利要求4所述的口蹄疫O型病毒sIgA抗体ELISA检测试剂盒,其特征在于,所述的口蹄疫O型病毒广谱多表位重组抗原包被的酶标板按照以下方法制备得到:
(1)包被抗原的制备和包被
原核表达系统表达获得的重组蛋白包涵体经复性及Ni-NTA纯化得到口蹄疫O型病毒广谱多表位重组抗原,其氨基酸序列如SEQ ID NO.2所示,包被时用pH9.6的碳酸盐缓冲液稀释至3μg/ml,按照100μl/孔包被酶标板,4℃冰箱静置过夜;
(2)酶标板的封闭与保存
包被过夜的酶标板用PBST洗涤4次拍干,每孔加100μl含0.5w/v%BSA的10mM PBS封闭液,37℃放置2h,弃掉封闭液,PBST洗涤3遍,得到预包被抗原的酶标板,每孔加100μl含6v/v%马血清的酶标板稳定剂,室温放置30min,弃掉液体后自然晾干,用铝箔袋真空封口,4℃保存;
其中,所述的酶标板稳定剂是将5g BSA、10g蔗糖、20g海藻糖,加入到1000ml 0.01mol/LPBS(pH7.4)中轻轻震荡至溶解,加0.05w/v%Procline300,保存于4℃备用。
7.如权利要求4所述的口蹄疫O型病毒sIgA抗体ELISA检测试剂盒,其特征在于,所述阳性对照样品是采集口蹄疫O型病毒攻毒后7-21d猪、牛以及羊的鼻拭子样品,经混合、一系列稀释后检测OD450值为1.5±0.05的样品;所述阴性样品是 FMDV NS试剂盒检测口蹄疫病毒非结构蛋白抗体为阴性,口蹄疫A型、O型、AsiaI液相阻断ELISA试剂盒检测血清抗体效价<1/4,FMDV特异性PCR检测抗原为阴性的猪、牛以及羊的鼻拭子,经混合、稀释后检测OD450值为0.1±0.05的样品,无菌分装备用。
8.如权利要求4所述的口蹄疫O型病毒sIgA抗体ELISA检测试剂盒,其特征在于,所述的100×浓缩酶标抗体为辣根过氧化物酶(HRP)标记鼠抗猪、牛或羊IgA的单克隆抗体,使用时,用酶标抗体稀释液100倍稀释后使用,所述的酶标抗体稀释液是含有1v/v%甘油、0.5w/v%牛血清白蛋白、1w/v%酪蛋白以及0.05w/v%Procline300的0.01mol/LPBS缓冲液,pH7.4。
9.如权利要求4所述的口蹄疫O型病毒sIgA抗体ELISA检测试剂盒,其特征在于,所述的样品稀释液为含0.5M NaCl、2.68mM KCl、2.79mM KH2PO4、8.1mM Na2HPO4、5g/L酪蛋白、0.05%Tween20和10mM PBS的混合溶液;所述的显色液为TMB显色液,所述的终止液为1moL/L H2SO4溶液;所述的浓缩洗涤液为10×PBST溶液,即含有0.5v/v%Tween20的0.1mol/L PBS溶液,pH 7.6,使用时稀释10倍。
10.如权利要求1所述的口蹄疫O型病毒sIgA抗体ELISA检测试剂盒,其特征在于,利用所述的试剂盒进行口蹄疫O型病毒sIgA抗体检测时,按照以下步骤进行:
(1)样本稀释
将待测样本、阳性对照以及阴性对照用样品稀释液按体积比1:2进行稀释;
(2)洗板
从4℃冰箱中取出口蹄疫O型病毒代表毒株主要中和性抗原表位(TB/O)蛋白包被的酶标板,打开铝箔袋,取出酶标板,以稀释好的洗涤液洗板3次,吸水纸拍干,每次3min;
(3)加样
将稀释后的待测样本、阳性对照以及阴性对照分别加入酶标板中,每孔100μL,37℃孵育45min;
(4)洗涤
取出酶标板,甩掉样品,用洗涤液漂洗4次,吸水纸拍干;
(5)加入酶标抗体
加入稀释好的辣根过氧化物酶标记的鼠抗猪、牛或羊IgA单克隆抗体,100μL/孔,37℃工作30min;
(6)加底物:
甩掉酶标抗体,用洗涤液漂洗4次,吸水纸拍干,加入显色液37℃显色15min,取出后立即加入终止液;
(7)结果判定
在酶标仪上读取OD450nm数值,待测样本的OD450nm值大于等于阴性对照样品平均值的2.5倍判为阳性,小于阴性对照样品平均值的2.5倍判为阴性。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811068030.0A CN109232720B (zh) | 2018-09-13 | 2018-09-13 | 一种口蹄疫O型病毒sIgA抗体ELISA检测试剂盒及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811068030.0A CN109232720B (zh) | 2018-09-13 | 2018-09-13 | 一种口蹄疫O型病毒sIgA抗体ELISA检测试剂盒及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109232720A true CN109232720A (zh) | 2019-01-18 |
| CN109232720B CN109232720B (zh) | 2021-11-23 |
Family
ID=65058301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811068030.0A Active CN109232720B (zh) | 2018-09-13 | 2018-09-13 | 一种口蹄疫O型病毒sIgA抗体ELISA检测试剂盒及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109232720B (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109655612A (zh) * | 2019-01-31 | 2019-04-19 | 中国农业科学院兰州兽医研究所 | 一种Asia1型口蹄疫病毒的检测试剂盒及检测方法 |
| CN110642945A (zh) * | 2019-10-25 | 2020-01-03 | 中国农业科学院兰州兽医研究所 | 一种通用型的口蹄疫病毒结构蛋白抗体及其阻断elisa检测试剂盒 |
| CN111574596A (zh) * | 2020-05-25 | 2020-08-25 | 中国农业科学院兰州兽医研究所 | 组成型分泌表达o型fmdv重组抗原表位基因工程cho细胞系的构建方法 |
| CN113267621A (zh) * | 2021-05-14 | 2021-08-17 | 北京金诺百泰生物技术有限公司 | 一种elisa试剂盒包被板用稳定剂及其制备方法、试剂盒包被板、试剂盒 |
| CN114705857A (zh) * | 2022-05-16 | 2022-07-05 | 北京亿森宝生物科技有限公司 | 猪口蹄疫病毒o型和a型抗体微孔板式化学发光检测试剂盒及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999066954A1 (en) * | 1998-06-20 | 1999-12-29 | United Biomedical Inc. | Synthetic peptide vaccines for foot-and-mouth disease |
| CN103897065A (zh) * | 2014-03-13 | 2014-07-02 | 中国农业科学院兰州兽医研究所 | 牛Asia1/O型口蹄疫双价多表位疫苗及其制备方法和应用 |
-
2018
- 2018-09-13 CN CN201811068030.0A patent/CN109232720B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999066954A1 (en) * | 1998-06-20 | 1999-12-29 | United Biomedical Inc. | Synthetic peptide vaccines for foot-and-mouth disease |
| CN103897065A (zh) * | 2014-03-13 | 2014-07-02 | 中国农业科学院兰州兽医研究所 | 牛Asia1/O型口蹄疫双价多表位疫苗及其制备方法和应用 |
Non-Patent Citations (2)
| Title |
|---|
| SM SABBIR ALAM 等: "Antigenic heterogeneity of capsid protein", 《ADVANCES AND APPLICATIONS IN BIOINFORMATICS AND CHEMISTRY》 * |
| 张中旺 等: "抗原表位的研究方法及口蹄疫病毒抗原表位的研究进展", 《微生物学报》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109655612A (zh) * | 2019-01-31 | 2019-04-19 | 中国农业科学院兰州兽医研究所 | 一种Asia1型口蹄疫病毒的检测试剂盒及检测方法 |
| CN110642945A (zh) * | 2019-10-25 | 2020-01-03 | 中国农业科学院兰州兽医研究所 | 一种通用型的口蹄疫病毒结构蛋白抗体及其阻断elisa检测试剂盒 |
| CN111574596A (zh) * | 2020-05-25 | 2020-08-25 | 中国农业科学院兰州兽医研究所 | 组成型分泌表达o型fmdv重组抗原表位基因工程cho细胞系的构建方法 |
| CN113267621A (zh) * | 2021-05-14 | 2021-08-17 | 北京金诺百泰生物技术有限公司 | 一种elisa试剂盒包被板用稳定剂及其制备方法、试剂盒包被板、试剂盒 |
| CN114705857A (zh) * | 2022-05-16 | 2022-07-05 | 北京亿森宝生物科技有限公司 | 猪口蹄疫病毒o型和a型抗体微孔板式化学发光检测试剂盒及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109232720B (zh) | 2021-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109187993A (zh) | 一种口蹄疫A型病毒sIgA抗体ELISA检测试剂盒及其应用 | |
| CN109232720A (zh) | 一种口蹄疫O型病毒sIgA抗体ELISA检测试剂盒及其应用 | |
| CN113956362B (zh) | 一种重组猫细小病毒vp2蛋白抗原及其在抗体诊断和疫苗制备中的应用 | |
| CN108761074A (zh) | 塞内卡病毒elisa抗体检测试剂盒及制备方法、应用 | |
| CN108872575A (zh) | 一种塞尼卡谷病毒非结构蛋白3abc抗体elisa检测试剂盒 | |
| Zhang et al. | Development and evaluation of a VP3-ELISA for the detection of goose and Muscovy duck parvovirus antibodies | |
| CN110554187B (zh) | 一种用于检测牛病毒性腹泻病毒抗体的表达蛋白、elisa试剂盒及其制备方法和应用 | |
| US11958883B2 (en) | Recombinant canine parvovirus 2a VP2 and 2b VP2 antigen protein, and use thereof | |
| CN108776225A (zh) | 猪细小病毒VLPs抗体检测试剂盒及其制备方法、应用 | |
| CN102680699B (zh) | 鉴别i群禽腺病毒感染的elisa检测方法 | |
| CN101819209A (zh) | 一种利用斑点免疫金渗滤法检测口蹄疫非结构蛋白3ab抗体的检测方法 | |
| CN104991061B (zh) | 基于ipma的小反刍兽疫病毒抗体检测试剂盒 | |
| CN114839368A (zh) | 一种猪盖他病毒间接elisa抗体检测方法及其试剂盒 | |
| CN109762052A (zh) | 猪圆环病毒3型Cap重组蛋白及其编码基因和应用 | |
| CN108101974A (zh) | 肝片吸虫多表位融合诊断抗原及其应用和制备方法 | |
| CN105267989A (zh) | 一种新型水溶性免疫佐剂棘球蚴疫苗 | |
| US20220016236A1 (en) | Recombinant porcine parvovirus antigenic protein and use thereof | |
| CN100334108C (zh) | 重组赤羽病毒核衣壳蛋白、其制备方法及应用 | |
| CN102495209B (zh) | 基于33k蛋白的favi抗体间接elisa检测试剂盒及其应用 | |
| CN111537736A (zh) | 一种鸡毒支原体抗体的间接elisa检测试剂盒及检测方法 | |
| CN104391112A (zh) | 检测牛副流感病毒3型抗体的表达蛋白及elisa试剂盒 | |
| CN109655610A (zh) | 一种伪狂犬病病毒的间接elisa检测试剂盒 | |
| CN115873077A (zh) | 检测牛结节性皮肤病病毒抗体的试剂及其所用多肽 | |
| CN114487397A (zh) | 一种用于检测猪丁型冠状病毒的间接elisa检测试剂盒 | |
| CN116203245A (zh) | 一种盖塔病毒抗体胶体金免疫层析试纸条及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |